TJX Companies Total Cost of Revenue decreased by 19.8% to $9.84B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 6.5%, from $9.25B to $9.84B. Over 4 years (FY 2022 to FY 2026), Total Cost of Revenue shows an upward trend with a 5.3% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
An increase relative to revenue suggests rising production costs or margin compression, while a decrease suggests improved operational efficiency.
Total cost of revenue includes the direct costs attributable to the production of goods or the delivery of services sold...
Varies by industry; for medical device manufacturers, this includes significant manufacturing and supply chain costs.
total_cost_of_revenue| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 | Q4 '26 | Q1 '27 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $7.26B | $8.53B | $8.84B | $9.30B | $8.22B | $8.57B | $8.62B | $9.73B | $8.37B | $8.91B | $9.14B | $10.21B | $8.74B | $9.38B | $9.62B | $9.70B | $9.25B | $9.98B | $10.19B | $12.27B | $9.84B |
| QoQ Change | — | +17.5% | +3.6% | +5.2% | -11.5% | +4.2% | +0.6% | +12.8% | -13.9% | +6.4% | +2.6% | +11.7% | -14.4% | +7.3% | +2.6% | +0.8% | -4.7% | +7.9% | +2.1% | +20.4% | -19.8% |
| YoY Change | — | — | — | — | +13.3% | +0.5% | -2.4% | +4.6% | +1.8% | +4.0% | +6.0% | +5.0% | +4.4% | +5.3% | +5.3% | -5.0% | +5.8% | +6.4% | +5.9% | +26.5% | +6.5% |